Brokerages predict that Stryker Co. (NYSE:SYK) will post earnings of $2.16 per share for the current quarter, according to Zacks. Eleven analysts have made estimates for Stryker’s earnings, with estimates ranging from $2.14 to $2.17. Stryker reported earnings of $1.96 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.2%. The firm is expected to report its next quarterly earnings report on Tuesday, January 29th.
On average, analysts expect that Stryker will report full-year earnings of $7.28 per share for the current year, with EPS estimates ranging from $7.24 to $7.30. For the next fiscal year, analysts expect that the firm will report earnings of $8.01 per share, with EPS estimates ranging from $7.89 to $8.14. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 25th. The medical technology company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.01. The business had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.26 billion. Stryker had a return on equity of 28.00% and a net margin of 9.31%.
Several brokerages recently issued reports on SYK. Cowen set a $195.00 price target on Stryker and gave the company a “buy” rating in a report on Friday, November 9th. Barclays began coverage on Stryker in a report on Monday, October 15th. They issued an “overweight” rating and a $198.00 price target for the company. Zacks Investment Research downgraded Stryker from a “buy” rating to a “hold” rating in a report on Monday, December 3rd. JPMorgan Chase & Co. increased their price target on Stryker to $200.00 and gave the company an “overweight” rating in a report on Thursday, September 13th. Finally, Oppenheimer set a $170.00 price target on Stryker and gave the company a “hold” rating in a report on Friday, October 26th. Eight equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $182.45.
In other Stryker news, VP M Kathryn Fink sold 415 shares of the company’s stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $166.56, for a total value of $69,122.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Glenn S. Boehnlein sold 750 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $178.17, for a total transaction of $133,627.50. Following the completion of the transaction, the chief financial officer now directly owns 2,785 shares of the company’s stock, valued at $496,203.45. The disclosure for this sale can be found here. Corporate insiders own 7.40% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Rehmann Capital Advisory Group boosted its position in Stryker by 3,030.1% in the 3rd quarter. Rehmann Capital Advisory Group now owns 207,713 shares of the medical technology company’s stock valued at $36,906,000 after buying an additional 201,077 shares during the last quarter. Carnegie Capital Asset Management LLC lifted its position in shares of Stryker by 1.2% during the third quarter. Carnegie Capital Asset Management LLC now owns 43,315 shares of the medical technology company’s stock worth $7,458,000 after purchasing an additional 530 shares during the last quarter. Reynders McVeigh Capital Management LLC lifted its position in shares of Stryker by 2.9% during the third quarter. Reynders McVeigh Capital Management LLC now owns 122,940 shares of the medical technology company’s stock worth $21,844,000 after purchasing an additional 3,455 shares during the last quarter. Central Bank & Trust Co. lifted its position in shares of Stryker by 5.1% during the third quarter. Central Bank & Trust Co. now owns 42,746 shares of the medical technology company’s stock worth $7,595,000 after purchasing an additional 2,063 shares during the last quarter. Finally, Belpointe Asset Management LLC bought a new position in shares of Stryker during the third quarter worth about $212,000. 74.72% of the stock is owned by institutional investors.
Shares of NYSE SYK opened at $168.85 on Wednesday. Stryker has a 12-month low of $146.80 and a 12-month high of $179.84. The firm has a market capitalization of $64.45 billion, a P/E ratio of 26.02, a P/E/G ratio of 2.36 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.21.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 31st. Shareholders of record on Monday, December 31st will be given a $0.52 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.47. This represents a $2.08 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Friday, December 28th. Stryker’s dividend payout ratio is presently 28.97%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Fundamental Analysis and Individual Investors
Get a free copy of the Zacks research report on Stryker (SYK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.